Nozinan (Levomepromazine)

Levomepromazine, the active ingredient in Nozinan, is a phenothiazine presented as a strength/form for oral use. It is employed in the management of severe agitation, nausea, and pain, particularly in palliative care settings and among adult patients. GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine is a phenothiazine antipsychotic that acts on multiple neurotransmitter pathways to provide symptom control in several serious conditions.

- Severe agitation in palliative care: helps calm patients experiencing extreme restlessness. - Nausea and vomiting associated with chemotherapy: reduces the frequency and intensity of episodes. - Chronic pain management: enhances analgesia when used as an adjunct. - Schizophrenia resistant to other treatments: offers an alternative when first‑line agents fail. - Pre‑operative anesthesia preparation: used to sedate patients before surgery.

Levomepromazine may elicit a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Drowsiness: feeling    - Dry dry   - Constipation   - Blurred   - Orthostatic   -     

Serious or Rare ":   -   g    -  

Lev…

...